Long-term remission is higher with an 18-month fixed rituximab regimen compared with azathioprine or 18-month tailored rituximab. Introduction ANCA-associated vasculitis (shortened to AAV), is a rare group of diseases of the immune system. These diseases are linked to a type of autoantibody called ANCA. An antibody is a protein that the normal healthy immune system […]
Category: ANCA-associated vasculitis
Dupilumab may be effective in treating EGPA-related ENT manifestations
Dupilumab appears attractive for the treatment of refractory EGPA-related asthma and ENT manifestations. Introduction ANCA-associated vasculitis (shortened to AAV), is a rare group of diseases of the immune system. It causes damage to small blood vessels. Any part of the body can be affected, but it most often affects the small blood vessels of a […]
An end to steroid treatment alongside rituximab maintenance in AAV?
Long-term use of even low-dose glucocorticoid for remission maintenance might not be necessary. Introduction ANCA-associated vasculitis (shortened to AAV), is a rare group of diseases of the immune system. These diseases are linked to a type of autoantibody called ANCA. An antibody is a protein that the normal healthy immune system makes to attack foreign […]
Updated: Managing AAV
This is the lay version of the EULAR recommendations for the management of people with a type of vasculitis associated with an antibody called antineutrophil cytoplasmic antibody. This name of this disease is often shortened to ANCA-associated vasculitis, or AAV. The original publication can be downloaded from the EULAR website: www.eular.org. Hellmich B, Sanchez-Alamo B, […]
Mycophenolate mofetil achieves remission in AAV
MMF is non-inferior to cyclophosphamide for achieving remission in people AAV, but results in higher relapse rate. Introduction ANCA-associated vasculitis (shortened to AAV), is a rare group of diseases that are very serious, and can be life-threatening. These diseases are linked to a type of autoantibody called ANCA. An antibody is a protein that the […]
Tailored treatment may be a possibility for AAV in people with GPA or MPA
AAV relapse rates did not significantly differ between individually tailored and fixed schedule rituximab regimens. Introduction Granulomatosis is a medical term for a disease where granulomas – or clusters of certain cell types – are formed. This can happen in immune or inflammatory diseases. People can have with granulomatosis with polyangiitis (also known as Wegener’s […]
Newly updated advice on the treatment of patients with AAV
INTRODUCTION A central focus of newly updated recommendations on treating ANCA-associated vasculitis (AAV) is shared decision-making between patients and doctors. The updated recommendations, produced by a collaboration between the European League Against Rheumatism (EULAR) and European Renal Association – European Dialysis and Transplant Association (ERA-EDTA), taking account of recent research on the benefits and safety […]
